An Assessment of the Formulated Medicated Transdermal Patches Containing an Antidiabetic Drug: an in-Vitro Study

Description

Abstract (English)

Conflict of interest: Nil
Abstract
Aim: The current research aims to formulate and evaluated medicated transdermal patches
containing an antidiabetic drug.
Material & Methods: In the present study was conducted by the Department of
Pharmacology, DMCH, Laheriasarai, Darbhanga, Bihar, India. An attempt has been made to
develop a matrix-type transdermal therapeutic system comprising of various PVP K30, MC
ratios and solvent evaporation techniques. A good penetration enhancer would improve drug
delivery from various polymer-based transdermal patches. Transdermal patches of the matrix
type are made. All prepared formulations were tested for weight variation, thickness, drug
content, moisture content, moisture uptake, flatness, and in vitro drug release. Bath F3 was
optimised formula from all formulation baths shows linear zero order release for 24 hours,
with a cumulative percentage of drug diffusion of 87.35% from 4cm2 patches. It has been
determined that polymer concentration.
Results: The formulated films were examined for colour, clearness, softness and elasticity. It
was précised by digital Vernier calipers. Three reading were taken for standard deviation
after thickness measured at five various site of patch. The thickness of Glimepiride patches
were between112.48-124.26μm. The folding endurance of patches was found to be
satisfactory between 121.49±2.36 to 128.42±0.46. This shows that patches would maintain
their integrity and not break easily. The moisture content in the patches was ranged from 1.38
± 0.26 to 2.80 ± 0.20% (for formulation F series and formulation respectively). The weight
variation of Glimepiride patches were in between 250 to 280 mg. This showed uniformity in
weight of patches while the % drug content of Glimepiride in patches were between 96.00 to
95.15±0.85% this shows passable drug content in patches.
Conclusion: When the concentration of PVP K30 increases in the primary layer, the in –
vitro diffusion rate increases, and when the concentration of PVP K30 decreases, the drug
diffusion decreases. It allows for more controlled drug release from the patch.